About Aditi Ganguly
Aditi is an experienced content developer and financial writer who is passionate about helping investors understand the do's and don'ts of investing. She has a keen interest in the stock market and has a fundamental approach when analyzing equities.
Aditi's fascination with the stock market began in college, where she majored in Economics, while researching The Great Recession for her thesis. After graduating, she began her career handling the content requirements for the mutual fund aggregator Groww. Since then she has become a financial journalist that focuses on writing articles that educate retail investors about the equity markets and the global economy.
Recent Articles By Aditi Ganguly
4 Green Energy Stocks to GROW Your Portfolio
A combination of catalysts is brewing for green energy companies. This includes a desire to reduce pollution in many countries, an aggresive alt energy stimulus plan proposed by Joe Biden, and increased efficiencies. Green energy companies such as Sunrun (RUN), Workhorse Group (WKHS), Azure Power Global (AZRE), and Pacific Ethanol (PEIX) will outperform in the upcoming years.
Will Shares of DraftKings Continue to Soar?
Draftkings (DKNG) is well positioned to maintain its momentum even after gaining 200% since its debut, owing to its growth potential, impressive past performance, favorable analyst sentiment and underlying industry strength.
An Entertainment Stock Showing Strength Amid Market Weakness
Comcast (CMCSA) is well positioned to move higher owing to its promising business outlook, solid past performance, short- and long-term bullishness and underlying industry strength.
Buy the Dips in These 3 Tech ETFs
The tech industry has dropped by around 15% in September. However, the sector's long-term fundamentals such as earnings growth remain solid. ETFs such as Vanguard Information Tech ETF (VGT), iShares Expanded Tech Software Sector ETF (IGV), and First Trust ISE Cloud computing Index Fund (SKYY) will outperform in the coming months.
Why You Should Add This Vaccine Maker to Your Portfolio Now
Merck’s (MRK) unique approach to developing a coronavirus vaccine may yield better results than its competitors. Further, the stock pays an above-average dividend, has a pipeline of promising drugs, and a track record of developing blockbuster drugs.
3 ETFs to Buy as "Market Rotation" Out of Tech Stocks Begins
With the United States gradually recovering from the pandemic-induced recession, the market rotation out of the high-flying tech sector has started. As the focus has primarily been shifting to consumer discretionary and financial services, the following ETFs should benefit: Consumer Discretionary Select SPDR ETF (XLY), the iShares U.S. Financial Services ETF (IYG), and the Vanguard Small-Cap Value ETF (VBR).
Should You 'Buy the Dip' in Abbott Laboratories?
Abbott Laboratories (ABT) is expected to soar in the upcoming months based on its impressive financial performance, favorable analyst sentiment, and rising demand for its recently launched COVID-19 testing kit.
3 Biotech Stocks with STRONG Momentum
TG Therapeutics (TGTX), Mesoblast (MESO), and Trillium Therapeutics (TRIL) are close to gaining approval for potentially blockbuster drugs. Their stocks are rising in anticipation. Find out whether you should invest.
Is Pfizer Stock a Buy?
Pfizer (PFE) is one of the leading drug manufacturers that’s in the race for developing a coronavirus vaccine. This, along with its sound financials, make it a good stock to buy right now.